EFTUD2

Across TCGA pan-cancer cohorts, EFTUD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EFTUD2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EFTUD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EFTUD2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where EFTUD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.835	1.000	.001	50	view →
HNSC	DFS	Tertile	III,IV	0.286	1.000	.006	37	view →
LSCC	DFS	Median	II,III,IV	0.850	0.544	.013	7	view →
LUAD	DFS	Tertile	III,IV	0.928	0.552	.030	4	view →
GBM	DFS	Quartile	All	0.466	0.310	.037	3	view →
PDAC	OS	Tertile	All	0.743	0.956	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EFTUD2–CCRCC (OS)

Open the CCRCC breakdown →